What are the results of the clinical trial and where can I find out more?Updated 3 months ago

In our 12-month, randomized, double-blind, placebo-controlled 
clinical study published in Osteoporosis International of 286 early postmenopausal women, Bōndia™ significantly
reduced bone loss across three high-risk groups.  

1. The largest improvements were seen in women with osteopenia. Bōndia slowed the rate of bone density loss by 85%. Those not taking it lost 6.5x as much bone density as the Bōndia group. Density was most preserved in the femoral neck—the region most involved in hip fractures.
2. Women with a BMI ≥ 30 showed significant improvements. Bōndia slowed the rate of bone density loss by 75%. Those not taking it lost 4.1x as much bone density as the Bōndia group. The improvement was observed throughout the hip bones.
3. Women with higher body fat composition (≥ 40%) also showed a benefit, even if their BMI is below 30. Bōndia slowed the rate of bone density loss by 60%. Those not taking it lost 2.5x as much bone density as the Bōndia group. The improvement was observed throughout the hip bones.
4. Improvements in rate of bone loss compound over time. A 0.25% versus 1.5% annual decline in bone density represents a difference that becomes increasingly meaningful—one that, when projected over several years, adds up to dramatically different outcomes for bone health over time.